Pfizer to supply U.S. with 100 million more COVID-19 shots by July By Reuters

<iframe src=”//″ width=”250″ height=”250″ scrolling=”no” border=”0″ marginwidth=”0″ style=”border:none;” frameborder=”0″></iframe>

© Reuters. Pfizer-BioNTech coronavirus disease (COVID-19) vaccination in New York

(Reuters) -Pfizer Inc will supply the United States with 100 million additional doses of its COVID-19 vaccine by July next year, the U.S. drugmaker said on Wednesday.

The agreement brings the total number of doses to be delivered to the United States to 200 million, allowing for 100 million people to be vaccinated.

Pfizer (NYSE:) and German partner BioNTech SE (NASDAQ:) will deliver at least 70 million doses by June 30, with the balance of the 100 million doses to be delivered no later than July 31, the company said.

The U.S. government will pay $1.95 billion for the additional 100 million doses, bringing the total paid to Pfizer to nearly $4 billion.

The government already has a deal with Pfizer for 100 million doses of the vaccine, which are being rolled out across the country after the shot won emergency use authorization earlier this month.

Pfizer’s two-dose shot is one of the two granted emergency approval in the United States, the other being rival Moderna (NASDAQ:) Inc’s vaccine based on a similar technology. The new deal will help the United States bolster its vaccine supply, as it grapples with a nationwide spike in infections that added more than a million new cases in just six days, according to a Reuters tally. More than 600,000 Americans have received their first COVID-19 vaccine doses as of Monday, according to the Centers for Disease Control and Prevention (CDC).

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.